Pomerantz LLP is investigating potential securities fraud claims on behalf of investors in CVRx, Inc. (NASDAQ: CVRX). The probe follows significant stock declines and revised revenue guidance.

The investigation centers on whether the company and its officers engaged in unlawful business practices. It stems from a series of negative developments between April 2025 and August 2026.

Timeline of Declines

On April 7, 2025, CVRx announced weaker than expected preliminary first quarter results. CEO Hykes noted that many newer sales representatives were still in early development stages. The stock fell $5.34 per share, or 46.3%, to close at $6.20 per share on April 8, 2025.

In May 2025, the company reported weak first quarter results and lowered full year revenue guidance. Hykes stated that salesforce changes were more significant than anticipated, with 25% of current territory managers hired between December and March. The stock dropped $3.01 per share, or 38.7%, to close at $4.77 per share on May 9, 2025.

August 2026 Guidance Cut

On August 6, 2026, CVRx lowered its full-year revenue guidance to $58 million-$60 million from $63 million-$67 million. Management attributed this to rapid hiring straining onboarding processes and territory manager productivity ramp rates.

Management stated that slightly less than half of CVRx's regions experienced negative year-to-date implant growth. These regions had the highest turnover and least-tenured leaders. The company also cited a prolonged challenge with one of its largest Medicare Advantage payers.

Additionally, CVRx disclosed receiving a Department of Justice civil investigative demand in May 2026 concerning certain sales and marketing practices. Following this news, the stock fell $3.55 per share, or 59.76%, to close at $2.39 per share on August 7, 2026.

What the Numbers Show

The correlation between operational disclosures and stock performance is stark. Each major update regarding salesforce instability or regulatory scrutiny triggered double-digit percentage declines. The August 2026 drop of nearly 60% was the largest single-day decline recorded in the source, coinciding with both a material guidance reduction and the DOJ investigation disclosure.

Legal Context

Pomerantz LLP, founded by Abraham L. Pomerantz, specializes in corporate and securities class litigation. The firm has offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Jorey Chernett, a beneficial owner of more than 5.5% of CVRx Inc (NASDAQ: CVRX) shares, has urged the company’s board to initiate an immediate sale process.

The Pointillist Family Office founder delivered a letter to the board on August 24, 2026, arguing that a sale would unlock significant value for shareholders through the strategic acquisition of CVRx’s Barostim product.

Strategic Rationale

Chernett contends that Barostim holds unique value for large medical device companies with established infrastructure. He asserts that a sale could be accretive to an acquirer within twelve months, offering CVRx shareholders immediate value superior to standalone operations.

The letter highlights the strategic scarcity of Barostim as the only approved neuromodulation therapy for heart failure. Chernett argues that launching a sale process now, while the company retains cash and field momentum, will yield better outcomes than a forced sale due to depleted cash reserves later.

Proposed Actions

The shareholder calls on the board to take three specific steps:

• Retain an independent financial advisor to review strategic alternatives, prioritizing a sale.
• Aggressively cut executive compensation and general and administrative expenses.
• Suspend incremental standalone spending commitments during the review period.

Chernett emphasizes that the board must commit to a clear timeline and move with urgency rather than waiting for financial pressure to dictate terms.